Insight

Julie Hallet: Guidance on biomarkers gene therapy for NETs

Photo of Julie Hallet from cpd.utoronto.ca

Dec 16, 2024, 19:07

Julie Hallet: Guidance on biomarkers gene therapy for NETs

Julie Hallet, Assistant Professor of Surgery at the University of Toronto, shared a post on X:

“My Top 10 articles of 2024 (cont’d)

Guidance on biomarkers gene therapy for NETs

JAMA Oncology by NANETS and CommNETs

Few are treatment-informing
Most need further research, including NGS, TMB, NETPET score

Which markers do NETologists currently use?

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

Authors: Jonathan M. Loree, David Chan, Jennifer Lim, Heather Stuart, Nicolas Fidelman, Jonathan Koea, Jason Posavad, Meredith Cummins, Sarah Doucette, Sten Myrehaug, Boris Naraev, Dale L. Bailey, Andrew Bellizzi, David Laidley, Veronica Boyle, Rachel Goodwin, Jaydi del Rivero, Michael Michael, Janice Pasieka, Simron Singh.”

Julie Hallet: Guidance on biomarkers gene therapy for NETs

Andrew Bellizzi Boris Naraev cancer Dale L. Bailey David Chan David Laidley Heather Stuart JAMA Oncology Janice Pasieka Jason Posavad Jaydi Del Rivero Jennifer Lim Jonathan Koea Jonathan M. Loree Julie Hallet Meredith Cummins Michael Michael NANETS NETologist NETPET NETs NGS Nicolas Fidelman OncoDaily Oncology Rachel Goodwin Sarah Doucette Simron Singh Sten Myrehaug TMB Veronica Boyle

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage